An inhibitor of thrombin activated fibrinolysis inhibitor (TAFI) can reduce extracellular matrix accumulation in an in vitro model of glucose induced ECM expansion

Matrix Biology

Volumn 32, Issue 5, 2013, Pages 277-287

  Atkinson, J M ^a   Pullen, N ^b   Johnson, T S ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b PFIZER INC   (United States)

Author keywords

Extracellular matrix; TAFI; TAFI inhibition; Thrombin activated fibrinolytic inhibitor plasmin

Indexed keywords

5 AMINO 2 [(1 N PROPYL 1H IMIDAZOL 4 YL)METHYL]PENTANOIC ACID; COLLAGEN; FIBRONECTIN; GLUCOSE; PLASMIN; THROMBIN; THROMBIN ACTIVATED FIBRINOLYSIS INHIBITOR; THROMBIN INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL GROWTH; CONTROLLED STUDY; DIABETIC NEPHROPATHY; ENZYME ACTIVITY; EXTRACELLULAR MATRIX; FIBRINOLYSIS; FIBROBLAST; IN VITRO STUDY; KIDNEY TUBULE EPITHELIUM; MESANGIUM CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROCESSING; RAT; RNA INTERFERENCE;

AMINO ACIDS; ANIMALS; CARBOXYPEPTIDASE U; CELL LINE; ENZYME INHIBITORS; EPITHELIAL CELLS; EXTRACELLULAR MATRIX; FIBRINOLYSIN; FIBRINOLYSIS; GENE EXPRESSION; GLUCOSE; HUMANS; IMIDAZOLES; KIDNEY TUBULES, PROXIMAL; MODELS, BIOLOGICAL; RATS; RENAL INSUFFICIENCY, CHRONIC; RNA, SMALL INTERFERING; THROMBIN;

EID: 84879602453     PISSN: 0945053X     EISSN: 15691802     Source Type: Journal    
DOI: 10.1016/j.matbio.2013.01.006     Document Type: Article

References (41)

1. Ayo S.H., Radnik R.A., et al. High glucose causes an increase in extracellular matrix proteins in cultured mesangial cells. Am. J. Pathol. 1990, 136(6):1339-1348.
2. Bajzar L., Manuel R., et al. Purification and characterization of TAFI, a thrombin-activable fibrinolysis inhibitor. J. Biol. Chem. 1995, 270(24):14477-14484.
3. Bajzar L., Morser J., et al. TAFI, or plasma procarboxypeptidase B, couples the coagulation and fibrinolytic cascades through the thrombin-thrombomodulin complex. J. Biol. Chem. 1996, 271(28):16603-16608.
4. Benyon R.C., Arthur M.J. Extracellular matrix degradation and the role of hepatic stellate cells. Semin. Liver Dis. 2001, 21(3):373-384.
5. Bruno N.E., Yano Y., et al. Protective role of thrombin activatable fibrinolysis inhibitor in obstructive nephropathy-associated tubulointerstitial fibrosis. J. Thromb. Haemost. 2008, 6(1):139-146.
6. Bruno N.E., Yano Y., et al. Immune complex-mediated glomerulonephritis is ameliorated by thrombin-activatable fibrinolysis inhibitor deficiency. Thromb. Haemost. 2008, 100(1):90-100.
7. Buelens K., Hassanzadeh-Ghassabeh G., et al. Generation and characterization of inhibitory nanobodies towards thrombin activatable fibrinolysis inhibitor. J. Thromb. Haemost. 2010, 8(6):1302-1312.
8. Bunnage M.E., Blagg J., et al. Discovery of potent & selective inhibitors of activated thrombin-activatable fibrinolysis inhibitor for the treatment of thrombosis. J. Med. Chem. 2007, 50(24):6095-6103.
9. Carrell R.W., Boswell D.R. Serpins: the superfamily of plasma serine protease inhibitors. Proteinase Inhibitors 1986, 403-420. S. Barret (Ed.).
10. Cheng S., Pollock A.S., et al. Matrix metalloproteinase 2 and basement membrane integrity: a unifying mechanism for progressive renal injury. FASEB J. 2006, 20(11):1898-1900.
11. Cho J., Seo H., et al. In vitro and in vivo studies of AT-1362, a newly synthesized and orally active inhibitor of thrombin. Thromb. Res. 2000, 100(1):97-107.
12. Collins S.J., Alexander S.L., et al. Plasminogen activator inhibitor-1 deficiency has renal benefits but some adverse systemic consequences in diabetic mice. Nephron Exp. Nephrol. 2006, 104(1):e23-34.
13. Eddy A.A. Serine proteases, inhibitors and receptors in renal fibrosis. Thromb. Haemost. 2009, 101(4):656-664.
14. Eddy A.A., Fogo A.B. Plasminogen activator inhibitor-1 in chronic kidney disease: evidence and mechanisms of action. J. Am. Soc. Nephrol. 2006, 17(11):2999-3012.
15. Fisher M., Jones R.A., et al. Modulation of tissue transglutaminase in tubular epithelial cells alters extracellular matrix levels: a potential mechanism of tissue scarring. Matrix Biol. 2009, 28(1):20-31.
16. Furugohri T., Isobe K., et al. DU-176b, a potent and orally active factor Xa inhibitor: in vitro and in vivo pharmacological profiles. J. Thromb. Haemost. 2008, 6(9):1542-1549.
17. Inbal A., Lubetsky A., et al. Impaired wound healing in factor XIII deficient mice. Thromb. Haemost. 2005, 94(2):432-437.
18. Lijnen H.R. Plasmin and matrix metalloproteinases in vascular remodeling. Thromb. Haemost. 2001, 86(1):324-333.
19. Lloyd C.M., Minto A.W., et al. RANTES and monocyte chemoattractant protein-1 (MCP-1) play an important role in the inflammatory phase of crescentic nephritis, but only MCP-1 is involved in crescent formation and interstitial fibrosis. J. Exp. Med. 1997, 185(7):1371-1380.
20. Ma L.J., Nakamura S., et al. Regression of glomerulosclerosis with high-dose angiotensin inhibition is linked to decreased plasminogen activator inhibitor-1. J. Am. Soc. Nephrol. 2005, 16(4):966-976.
21. Ma J., Weisberg A., et al. Plasminogen activator inhibitor-1 deficiency protects against aldosterone-induced glomerular injury. Kidney Int. 2006, 69(6):1064-1072.
22. McLennan S.V., Fisher E., et al. Effects of glucose on matrix metalloproteinase and plasmin activities in mesangial cells: possible role in diabetic nephropathy. Kidney. Int. Suppl. 2000, 77:S81-87.
23. Montgomery A.M., De Clerck Y.A., et al. Melanoma-mediated dissolution of extracellular matrix: contribution of urokinase-dependent and metalloproteinase-dependent proteolytic pathways. Cancer Res. 1993, 53(3):693-700.
24. Nagashima M., Yin Z.F., et al. Thrombin-activatable fibrinolysis inhibitor (TAFI) deficient mice. Front. Biosci. 2002, 7:d556-568.
25. Nesheim M. Thrombin and fibrinolysis. Chest 2003, 124(3 Suppl.):33S-39S.
26. Nicholas S.B., Aguiniga E., et al. Plasminogen activator inhibitor-1 deficiency retards diabetic nephropathy. Kidney Int. 2005, 67(4):1297-1307.
27. Oda T., Jung Y.O., et al. PAI-1 deficiency attenuates the fibrogenic response to ureteral obstruction. Kidney Int. 2001, 60(2):587-596.
28. Pfaffl M.W. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 2001, 29(9):e45.
29. Rerolle J.P., Hertig A., et al. Plasminogen activator inhibitor type 1 is a potential target in renal fibrogenesis. Kidney Int. 2000, 58(5):1841-1850.
30. Singh R., Song R.H., et al. High glucose decreases matrix metalloproteinase-2 activity in rat mesangial cells via transforming growth factor-beta1. Exp. Nephrol. 2001, 9(4):249-257.
31. Skill N.J., Johnson T.S., et al. Inhibition of transglutaminase activity reduces extracellular matrix accumulation induced by high glucose levels in proximal tubular epithelial cells. J. Biol. Chem. 2004, 279(46):47754-47762.
32. Sorensen I., Susnik N., et al. Fibrinogen, acting as a mitogen for tubulointerstitial fibroblasts, promotes renal fibrosis. Kidney Int. 2011, 80(10):1035-1044.
33. te Velde E.A., Wagenaar G.T., et al. Impaired healing of cutaneous wounds and colonic anastomoses in mice lacking thrombin-activatable fibrinolysis inhibitor. J. Thromb. Haemost. 2003, 1(10):2087-2096.
34. Tobu M., Iqbal O., et al. Erythropoietin-induced thrombosis as a result of increased inflammation and thrombin activatable fibrinolytic inhibitor. Clin. Appl. Thromb. Hemost. 2004, 10(3):225-232.
35. Tomasi S., Sarmientos P., et al. Mutant prourokinase with adjunctive C1-inhibitor is an effective and safer alternative to tPA in rat stroke. PLoS One 2011, 6(7):e21999.
36. Vassalli J.D., Sappino A.P., et al. The plasminogen activator/plasmin system. J. Clin. Invest. 1991, 88(4):1067-1072.
37. Wang W., Hendriks D.F., et al. Carboxypeptidase U, a plasma carboxypeptidase with high affinity for plasminogen. J. Biol. Chem. 1994, 269(22):15937-15944.
38. Wang Y.X., Zhao L., et al. A novel inhibitor of activated thrombin-activatable fibrinolysis inhibitor (TAFIa) - part I: pharmacological characterization. Thromb. Haemost. 2007, 97(1):45-53.
39. Yano Y., Kitagawa N., et al. Increased plasma thrombin-activatable fibrinolysis inhibitor levels in normotensive type 2 diabetic patients with microalbuminuria. J. Clin. Endocrinol. Metab. 2003, 88(2):736-741.
40. Yuan J.S., Reed A., et al. Statistical analysis of real-time PCR data. BMC Bioinforma. 2006, 7:85.
41. Yung S., Lee C.Y., et al. Elevated glucose induction of thrombospondin-1 up-regulates fibronectin synthesis in proximal renal tubular epithelial cells through TGF-beta1 dependent and TGF-beta1 independent pathways. Nephrol. Dial. Transplant. 2006, 21(6):1504-1513.